Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen–allergic patients

This publication has 32 references indexed in Scilit:

• Conditions in blood sampling procedures that extend the ex vivo stability of eosinophil activity markers in peripheral blood from allergic patients and healthy controls
  Annals of Allergy, Asthma & Immunology, 1999
• Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season☆☆☆★
  Journal of Allergy and Clinical Immunology, 1999
• Characterization of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma
  Clinical and Experimental Allergy, 1999
• Cytokines in asthma
  Thorax, 1999
• Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy
  International Archives of Allergy and Immunology, 1999
• The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma
  Allergy, 1996
• Anti-IgE–induced accumulation of leukocytes, mediators, and albumin in skin chamber fluid from healthy and atopic subjects
  Journal of Allergy and Clinical Immunology, 1996
• Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects
  Journal of Allergy and Clinical Immunology, 1995
• Eosinophils in the 1990s: New perspectives on their role in health and disease
  Postgraduate Medical Journal, 1994
• Counts of activated blood eosinophils for monitoring asthma
  Allergy, 1993